Abstract
Hepatorenal syndrome (HRS), a feared complication of advanced cirrhosis, is characterized by functional renal failure, secondary to renal vasoconstriction in the absence of underlying kidney pathology. Extreme underfilling of the arterial circulation, caused by arterial vasodilation of the splanchnic circulation, activates vasoconstrictor systems, which lead to intense renal vasoconstriction and HRS. Factors predictive for the development of HRS include intense urinary sodium retention, dilutional hyponatremia, low blood pressure, decreased cardiac output, and increased activity of systemic vasoconstrictors. The prognosis for patients with HRS is extremely poor, especially for those with the acute, progressive (type 1) form. Liver transplantation is the best treatment for suitable candidates and should always be the management option considered first. Pharmacologic therapies are aimed at improving renal function to enable patients to survive until transplantation is possible. These therapies are based on plasma expansion with albumin, combined with the use of either vasopressin analogs or α-adrenergic agonists. Other nonpharmacologic therapies, such as transjugular intrahepatic portosystemic shunts and albumin dialysis show promise, but experience with these treatments is limited. For prevention of HRS, albumin infusion is recommended in patients with spontaneous bacterial peritonitis, and pentoxifylline treatment is recommended in patients with acute alcoholic hepatitis.
Key Points
-
Hepatorenal syndrome (HRS) is at the end of a spectrum of functional renal abnormalities caused by a severe vasoconstriction of the renal circulation
-
Splanchnic vasodilation causing arterial underfilling, a compensatory neurohormonal response that leads to renal vasoconstriction, and a reduction in cardiac output seem to be the main factors responsible for the development of HRS
-
Type 1 HRS is an acute and rapidly progressive form with a very poor prognosis; type 2 HRS is a more stable form with a slightly better prognosis
-
HRS that develops in patients with cirrhosis after spontaneous bacterial peritonitis can be prevented by intravenous albumin and antibiotic therapy
-
Patients with HRS who are transplant candidates should be given high priority for liver transplantation
-
Therapy of HRS should be aimed at reversing the intense splanchnic arteriolar vasodilation with splanchnic vasoconstrictors and plasma expansion as a bridge to liver transplantation; the use of transjugular intrahepatic portosystemic shunt also seems to be effective in selected cases of HRS
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arroyo V et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23: 164–176
Ginès P et al. (2004) Management of cirrhosis and ascites. N Engl J Med 350: 1646–1654
Akriviadis E et al. (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 1637–1648
Moore K (1999) Renal failure in acute liver failure. Eur J Gastroenterol Hepatol 11: 967–975
Gines A et al. (1993) Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 105: 229–236
Alessandria C et al. (2005) MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41: 1282–1289
Sort P et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 5: 403–409
Epstein M et al. (1970) Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49: 175–185
Schrier RW et al. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151–1157
Iwakiri Y and Groszmann R (2006) The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43 (Suppl 1): S121–S131
Bernardi M and Domenicali M (2005) The renin–angiotensin–aldosterone system in cirrhosis. In Ascites and renal dysfunction in liver disease, 43–53 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
Dudley F and Esler M (2005) The sympathetic nervous system in cirrhosis. In Ascites and renal dysfunction in liver disease, 54–72 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
Ishikawa S and Schrier RW (2003) Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) 58: 1–17
Arroyo V and Colmenero J (2003) Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 38 (Suppl 1): S69–S89
Terra C et al. (2005) Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis. Value of MELD score. Gastroenterology 129: 1944–1953
Ruiz-del-Arbol L et al. (2005) Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42: 439–447
Ruiz-del-Arbol W et al. (2003) Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38: 1210–1218
Lenz K (2005) Hepatorenal syndrome—is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? Hepatology 42: 263–265
Cárdenas A and Ginès P (2005) Management of hyponatremia in cirrhosis. In Ascites and renal dysfunction in liver disease, 305–314 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
Caregaro L et al. (1994) Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 154: 201–205
Sherman D et al. (2003) Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 41: 269–278
Cárdenas A (2005) Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterology 100: 1–8
Ginès P et al. (1998) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94: 1493–1502
Follo A et al. (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20: 1495–1501
Angeli P et al. (2006) Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 23: 75–84
Cárdenas A et al. (2001) Renal failure after upper gastrointestinal bleeding in cirrhosis. Incidence, clinical course, predictive factors and short-term prognosis. Hepatology 34: 671–676
Guevara M et al. (2004) Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40: 646–651
Watt K et al. (2002) Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 97: 2046–2050
Servin-Abad L et al. (2005) Retrospective analysis of 140 patients labeled as hepatorenal syndrome in a referral center [abstract]. Hepatology 42: 543A
Fernandez J et al. (2005) A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42: 627–634
Rimola A et al. (2005) Liver transplantation for patients with cirrhosis and ascites. In Ascites and renal dysfunction in liver disease, 271–285 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
Cárdenas A and Ginès P (2005) Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 42 (Suppl 1): S124–S133
Restuccia T et al. (2004) Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case–control study. J Hepatol 40: 140–146
Testino G et al. (2003) Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent–shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 50: 1753–1755
Brensing KA et al. (2000) Long-term outcome after transjugular intrahepatic portosystemic stent–shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47: 288–295
Alessandria C et al. (2002) Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 14: 1363–1368
Arroyo V et al. (2005) Hepatorenal syndrome in cirrhosis: clinical features, diagnosis, and management. In Ascites and renal dysfunction in liver disease, 341–359 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
Angeli P et al. (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29: 1690–1697
Fevery J et al. (1990) Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 11: 153–158
Gines A et al. (1993) Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 17: 220–226
Soper CP et al. (1996) Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 347: 1842–1843
Holt S et al. (1999) Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353: 294–295
Guevara M et al. (1998) Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27: 35–41
Gulberg V et al. (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30: 870–875
Hadengue A et al. (1998) Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29: 565–570
Uriz J et al. (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33: 43–48
Moreau R et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122: 923–930
Ortega R et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 36: 41–48
Mulkay JP et al. (2001) Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 64: 15–19
Halimi C et al. (2002) Effect of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14: 153–158
Colle I et al. (2002) Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 17: 882–888
Solanki P et al. (2003) Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18: 152–156
Saner F et al. (2004) Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur J Med Res 9: 78–82
Saner FH et al. (2003) Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. Eur J Gastroenterol Hepatol 15: 925–927
Gluud LL et al. (2005) Terlipressin for hepatorenal syndrome. The Cochrane Database of Systematic Reviews J Hepatol 42 (Suppl 2): 81
Wong F et al. (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40: 55–64
Duvoux C et al. (2002) Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 36: 374–380
Arroyo V et al. (2005) Circulatory dysfunction in cirrhosis. In Update in Treatment of Liver Disease, 19–28 (Eds Arroyo V et al.) Barcelona: Ars Medica
Pomier-Layrargues G et al. (2003) Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 38: 238–243
Boyer TD and Haskal Z (2005) The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 41: 386–400
Guevara M et al. (1998) Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28: 416–422
D'Amico G et al. (2005) Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 129: 1282–1293
Albillos A et al. (2005) A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 43: 990–996
Kapling RK and Bastani B (2004) The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail 26: 563–568
Keller F et al. (1995) Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 17: 135–146
Mitzer SR et al. (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6: 277–286
Rifai K et al. (2005) The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 23: 298–302
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Cárdenas, A., Ginès, P. Therapy Insight: management of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol 3, 338–348 (2006). https://doi.org/10.1038/ncpgasthep0517
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0517
This article is cited by
-
Current Therapies for Hepatorenal Syndrome
Current Hepatology Reports (2014)
-
Hypoalbuminemia
Internal and Emergency Medicine (2012)